POSB74 Belantamab Mafodotin as the First-in-Class Anti-BCMA Treatment for Relapsed/Refractory Multiple Myeloma: A Budget Impact and Cost-Effectiveness Analysis
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.347
https://www.valueinhealthjournal.com/article/S1098-3015(21)02142-2/fulltext
Title :
POSB74 Belantamab Mafodotin as the First-in-Class Anti-BCMA Treatment for Relapsed/Refractory Multiple Myeloma: A Budget Impact and Cost-Effectiveness Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02142-2&doi=10.1016/j.jval.2021.11.347
First page :
Section Title :
Open access? :
No
Section Order :
11119